NEW YORK (GenomeWeb News) – BellBrook Labs today announced a revised distribution agreement with Cambio to include BellBrook's full Transcreener product line of HTS assays.

Under the terms of the revised deal, Cambio becomes the exclusive distributor of BellBrook's Transcreener HTS assays in the UK. Cambio will also distribute BellBrook's new Transzyme product line of turnkey methyltransferase assay kits combining precalibrated purified methytransferase enzymes and substrates from Reaction Biology with BellBrook's Transcreener Epigen Methyltransferase detection reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.